Bayer Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Bayer ha un patrimonio netto totale di €30.7B e un debito totale di €41.2B, che porta il suo rapporto debito/patrimonio netto a 134.1%. Le sue attività totali e le sue passività totali sono rispettivamente €106.9B e €76.3B. L'EBIT di Bayer è €9.2B rendendo il suo rapporto di copertura degli interessi 11.3. Ha liquidità e investimenti a breve termine pari a €6.3B.

Informazioni chiave

134.1%

Rapporto debito/patrimonio netto

€41.16b

Debito

Indice di copertura degli interessi	11.3x
Contanti	€6.34b
Patrimonio netto	€30.69b
Totale passività	€76.25b
Totale attività	€106.95b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( €33.1B ) di BAY superano le sue passività a breve termine ( €25.0B ).

Passività a lungo termine: Le attività a breve termine di BAY ( €33.1B ) non coprono le sue passività a lungo termine ( €51.2B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 113.5% ) di BAY è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di BAY è aumentato da 92.1% a 134.1% negli ultimi 5 anni.

Copertura del debito: Il debito di BAY non è ben coperto dal flusso di cassa operativo ( 19.4% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di BAY sono ben coperti dall'EBIT ( 11.3 x copertura).

Bayer Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Third quarter 2024 earnings released: €4.26 loss per share (vs €4.65 loss in 3Q 2023)

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

New minor risk - Share price stability

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

New minor risk - Share price stability

Second quarter 2024 earnings released: €0.03 loss per share (vs €1.92 loss in 2Q 2023)

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

First quarter 2024 earnings released: EPS: €2.04 (vs €2.22 in 1Q 2023)

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Full year 2023 earnings released: €2.99 loss per share (vs €4.22 profit in FY 2022)

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft, Annual General Meeting, Apr 26, 2024

Now 23% undervalued after recent price drop

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Williams Hart & Boundas Wins Against Bayer

Now 20% undervalued after recent price drop

Now 23% undervalued after recent price drop

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Third quarter 2023 earnings released: €4.66 loss per share (vs €0.56 profit in 3Q 2022)

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

New minor risk - Profit margin trend

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane